HUP0002053A3 - Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity - Google Patents
Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesityInfo
- Publication number
- HUP0002053A3 HUP0002053A3 HU0002053A HUP0002053A HUP0002053A3 HU P0002053 A3 HUP0002053 A3 HU P0002053A3 HU 0002053 A HU0002053 A HU 0002053A HU P0002053 A HUP0002053 A HU P0002053A HU P0002053 A3 HUP0002053 A3 HU P0002053A3
- Authority
- HU
- Hungary
- Prior art keywords
- obesity
- diabetes
- treatment
- benzenesulfonamides
- thiazole
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- MYEFHJZLNOFLNK-UHFFFAOYSA-N benzenesulfonamide;1,3-thiazole Chemical class C1=CSC=N1.NS(=O)(=O)C1=CC=CC=C1 MYEFHJZLNOFLNK-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0002053A2 HUP0002053A2 (hu) | 2001-08-28 |
| HUP0002053A3 true HUP0002053A3 (en) | 2001-09-28 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0002053A HUP0002053A3 (en) | 1997-01-28 | 1998-01-23 | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (hu) |
| JP (1) | JP2001509166A (hu) |
| KR (1) | KR20000070568A (hu) |
| CN (1) | CN1251099A (hu) |
| AR (1) | AR011092A1 (hu) |
| AU (1) | AU728812B2 (hu) |
| BG (1) | BG103686A (hu) |
| BR (1) | BR9807096A (hu) |
| CA (1) | CA2278739A1 (hu) |
| EA (1) | EA199900692A1 (hu) |
| EE (1) | EE9900328A (hu) |
| HR (1) | HRP980044A2 (hu) |
| HU (1) | HUP0002053A3 (hu) |
| ID (1) | ID22273A (hu) |
| IL (1) | IL131130A0 (hu) |
| IS (1) | IS5131A (hu) |
| NO (1) | NO993646L (hu) |
| PE (1) | PE52299A1 (hu) |
| PL (1) | PL334833A1 (hu) |
| SK (1) | SK100099A3 (hu) |
| TR (1) | TR199902442T2 (hu) |
| WO (1) | WO1998032753A1 (hu) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| TR200401359T4 (tr) | 2000-03-31 | 2004-08-23 | Pfizer Products Inc. | İkame edilmiş piridinlerin hazırlanmasına yönelik işlem |
| JP4988128B2 (ja) * | 2000-07-13 | 2012-08-01 | イーライ リリー アンド カンパニー | β３アドレナリン作動性アゴニスト |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| CA2421594A1 (en) | 2000-11-10 | 2002-05-16 | John Arnold Werner | 3-substituted oxindole beta 3 agonists |
| AU2002221080A1 (en) * | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| ES2255621T3 (es) * | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| DE60211199T2 (de) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol-beta-3-agonisten |
| ES2272749T3 (es) | 2001-08-14 | 2007-05-01 | Eli Lilly And Company | Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2. |
| CA2463441A1 (en) * | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| JP2005518357A (ja) | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ３アドレナリンアゴニスト |
| ATE297925T1 (de) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
| US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| WO2006132196A1 (ja) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β３作動薬を含有する新規な医薬 |
| PE20070458A1 (es) | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
| EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| EP1937264B1 (en) * | 2005-10-04 | 2011-06-08 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| WO2011097079A1 (en) | 2010-02-03 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 ID IDW990755A patent/ID22273A/id unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/pt not_active IP Right Cessation
- 1998-01-23 EE EEP199900328A patent/EE9900328A/xx unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/sk unknown
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/xx unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 IL IL13113098A patent/IL131130A0/xx unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 CN CN98803585A patent/CN1251099A/zh active Pending
- 1998-01-23 PL PL98334833A patent/PL334833A1/xx unknown
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/hu unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/ko not_active Application Discontinuation
- 1998-01-23 EA EA199900692A patent/EA199900692A1/ru unknown
- 1998-01-23 JP JP53214898A patent/JP2001509166A/ja active Pending
- 1998-01-27 AR ARP980100357A patent/AR011092A1/es unknown
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/hr not_active Application Discontinuation
- 1998-01-28 PE PE1998000064A patent/PE52299A1/es not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/is unknown
- 1999-07-27 NO NO993646A patent/NO993646L/no not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9807096A (pt) | 2000-04-18 |
| WO1998032753A1 (en) | 1998-07-30 |
| IS5131A (is) | 1999-07-23 |
| HUP0002053A2 (hu) | 2001-08-28 |
| ID22273A (id) | 1999-09-23 |
| EE9900328A (et) | 2000-02-15 |
| PE52299A1 (es) | 1999-05-26 |
| NO993646L (no) | 1999-09-27 |
| TR199902442T2 (xx) | 2000-07-21 |
| CA2278739A1 (en) | 1998-07-30 |
| AR011092A1 (es) | 2000-08-02 |
| PL334833A1 (en) | 2000-03-27 |
| EA199900692A1 (ru) | 2000-02-28 |
| HRP980044A2 (en) | 1998-10-31 |
| JP2001509166A (ja) | 2001-07-10 |
| AU6038498A (en) | 1998-08-18 |
| BG103686A (bg) | 2000-06-30 |
| NO993646D0 (no) | 1999-07-27 |
| AU728812B2 (en) | 2001-01-18 |
| EP0968209A1 (en) | 2000-01-05 |
| CN1251099A (zh) | 2000-04-19 |
| IL131130A0 (en) | 2001-01-28 |
| KR20000070568A (ko) | 2000-11-25 |
| SK100099A3 (en) | 2000-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL131130A0 (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| HU9602951D0 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| EP0915847A4 (en) | SUBSTITUTED SULPHONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETIS AND FAT addiction | |
| AU3374897A (en) | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| AP9901719A0 (en) | Treatment of diabetes with thiazolidinedione and metormin | |
| GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
| HK1045111A1 (en) | (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes | |
| HK1043954B (zh) | 生物量預水解的裝置及使用 | |
| HK1031174A1 (en) | Compositions and methods for treating diabetes | |
| HU9802721D0 (en) | Method and composition for the treatment and prevention of hyperuricemia | |
| IL128894A0 (en) | Materials and methods relating to the diagnosis and treatment of diabetes and obesity | |
| IL133136A0 (en) | Use of leptin antagonists for the treatment of diabetes | |
| HUP0003260A3 (en) | Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin | |
| EP0999848A4 (en) | CHIMEAN PROTEINS FOR TREATING DIABETES | |
| IL133907A0 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
| IL133137A0 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| IL134045A0 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| AU7595298A (en) | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension | |
| PL337577A1 (en) | Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor | |
| EP0969852A4 (en) | COMBINATION THERAPY OF AGENTS FOR THE TREATMENT OF DIABETES AND OBESITY | |
| GB9705041D0 (en) | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
| GB9614191D0 (en) | Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity | |
| GB9604102D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity |